Literature DB >> 15385485

Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain.

M W Goschnick1, C G Black, L Kedzierski, A A Holder, R L Coppel.   

Abstract

Immunization with merozoite surface protein 4/5 (MSP4/5), the murine malaria homologue of Plasmodium falciparum MSP4 and MSP5, has been shown to protect mice against challenge by parasites expressing the homologous form of the protein. The gene encoding MSP4/5 was sequenced from a number of Plasmodium yoelii isolates in order to assess the level of polymorphism in the protein. The gene was found to be highly conserved among the 13 P. yoelii isolates sequenced, even though many of the same isolates showed pronounced variability in their MSP1(19) sequences. Nonsynonymous mutations were detected only for the isolates Plasmodium yoelii nigeriensis N67 and Plasmodium yoelii killicki 193L and 194ZZ. Immunization and challenge of BALB/c mice showed that the heterologous MSP4/5 proteins were able to confer a level of protection against lethal Plasmodium yoelii yoelii YM challenge infection similar to that induced by immunization with the homologous MSP4/5 protein. To explore the limits of heterologous protection, mice were immunized with recombinant MSP4/5 protein from Plasmodium berghei ANKA and Plasmodium chabaudi adami DS and challenged with P. y. yoelii YM. Interestingly, significant protection was afforded by P. berghei ANKA MSP4/5, which shows 81% sequence identity with P. y. yoelii YM MSP4/5, but it was abolished upon reduction and alkylation. Significant protection was not observed for mice immunized with recombinant P. c. adami DS MSP4/5, which shows 55.7% sequence identity with P. y. yoelii YM MSP4/5. This study demonstrates the robustness of MSP4/5 in conferring protection against variant forms of the protein in a murine challenge system, in contrast to the situation found for other asexual-stage proteins, such as MSP1(19) and AMA1.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385485      PMCID: PMC517552          DOI: 10.1128/IAI.72.10.5840-5849.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  34 in total

1.  Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum.

Authors:  L Wang; C G Black; V M Marshall; R L Coppel
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

2.  Limited polymorphism of the vaccine candidate merozoite surface protein 4 of Plasmodium falciparum.

Authors:  Lina Wang; Vikki M Marshall; Ross L Coppel
Journal:  Mol Biochem Parasitol       Date:  2002-04-09       Impact factor: 1.759

3.  Synonymous and non-synonymous mutations in a region of the Plasmodium chabaudi genome and evidence for selection acting on a malaria vaccine candidate.

Authors:  C G Black; R L Coppel
Journal:  Mol Biochem Parasitol       Date:  2000-12       Impact factor: 1.759

4.  Immunization with recombinant Plasmodium yoelii merozoite surface protein 4/5 protects mice against lethal challenge.

Authors:  L Kedzierski; C G Black; R L Coppel
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodium yoelii.

Authors:  L Kedzierski; C G Black; R L Coppel
Journal:  Mol Biochem Parasitol       Date:  2000-01-05       Impact factor: 1.759

6.  Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii.

Authors:  Lukasz Kedzierski; Casilda G Black; Matthew W Goschnick; Anthony W Stowers; Ross L Coppel
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

7.  Lack of sequence diversity in the gene encoding merozoite surface protein 5 of Plasmodium falciparum.

Authors:  T Wu; C G Black; L Wang; A R Hibbs; R L Coppel
Journal:  Mol Biochem Parasitol       Date:  1999-10-15       Impact factor: 1.759

8.  Comparison of the protective efficacy of yeast-derived and Escherichia coli-derived recombinant merozoite surface protein 4/5 against lethal challenge by Plasmodium yoelii.

Authors:  L Kedzierski; C G Black; A W Stowers; M W Goschnick; D C Kaslow; R L Coppel
Journal:  Vaccine       Date:  2001-09-14       Impact factor: 3.641

9.  A protective glycosylphosphatidylinositol-anchored membrane protein of Plasmodium yoelii trophozoites and merozoites contains two epidermal growth factor-like domains.

Authors:  J M Burns; C C Belk; P D Dunn
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 10.  The economic and social burden of malaria.

Authors:  Jeffrey Sachs; Pia Malaney
Journal:  Nature       Date:  2002-02-07       Impact factor: 49.962

View more
  14 in total

1.  Predicting antidisease immunity using proteome arrays and sera from children naturally exposed to malaria.

Authors:  Olivia C Finney; Samuel A Danziger; Douglas M Molina; Marissa Vignali; Aki Takagi; Ming Ji; Danielle I Stanisic; Peter M Siba; Xiawu Liang; John D Aitchison; Ivo Mueller; Malcolm J Gardner; Ruobing Wang
Journal:  Mol Cell Proteomics       Date:  2014-07-14       Impact factor: 5.911

2.  Induction of strain-transcending immunity against Plasmodium chabaudi adami malaria with a multiepitope DNA vaccine.

Authors:  T Scorza; K Grubb; P Smooker; A Rainczuk; D Proll; T W Spithill
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

3.  Proteomic Analysis of Plasmodium Merosomes: The Link between Liver and Blood Stages in Malaria.

Authors:  Melanie J Shears; Raja Sekhar Nirujogi; Kristian E Swearingen; Santosh Renuse; Satish Mishra; Panga Jaipal Reddy; Robert L Moritz; Akhilesh Pandey; Photini Sinnis
Journal:  J Proteome Res       Date:  2019-07-23       Impact factor: 4.466

4.  Sequential processing of merozoite surface proteins during and after erythrocyte invasion by Plasmodium falciparum.

Authors:  Michelle J Boyle; Christine Langer; Jo-Anne Chan; Anthony N Hodder; Ross L Coppel; Robin F Anders; James G Beeson
Journal:  Infect Immun       Date:  2013-11-11       Impact factor: 3.441

5.  Limited global diversity of the Plasmodium vivax merozoite surface protein 4 gene.

Authors:  Chaturong Putaporntip; Somchai Jongwutiwes; Marcelo U Ferreira; Hiroji Kanbara; Rachanee Udomsangpetch; Liwang Cui
Journal:  Infect Genet Evol       Date:  2009-05-04       Impact factor: 3.342

6.  The antibody response to Plasmodium falciparum Merozoite Surface Protein 4: comparative assessment of specificity and growth inhibitory antibody activity to infection-acquired and immunization-induced epitopes.

Authors:  Harini D de Silva; Suha Saleh; Svetozar Kovacevic; Lina Wang; Casilda G Black; Magdalena Plebanski; Ross L Coppel
Journal:  Malar J       Date:  2011-09-16       Impact factor: 2.979

7.  Fast track antibody V-gene rescue, recombinant expression in plants and characterization of a PfMSP4-specific antibody.

Authors:  Stephanie Kapelski; Alexander Boes; Holger Spiegel; Melanie de Almeida; Torsten Klockenbring; Andreas Reimann; Rainer Fischer; Stefan Barth; Rolf Fendel
Journal:  Malar J       Date:  2015-02-05       Impact factor: 2.979

8.  Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals.

Authors:  Damon P Eisen; Lina Wang; Helene Jouin; E Elsa H Murhandarwati; Casilda G Black; Odile Mercereau-Puijalon; Ross L Coppel
Journal:  Malar J       Date:  2007-07-02       Impact factor: 2.979

9.  AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5.

Authors:  Gustavo Bracho; Caridad Zayas; Lina Wang; Ross Coppel; Oliver Pérez; Nikolai Petrovsky
Journal:  Malar J       Date:  2009-02-27       Impact factor: 2.979

Review 10.  The role played by alternative splicing in antigenic variability in human endo-parasites.

Authors:  Rodney Hull; Zodwa Dlamini
Journal:  Parasit Vectors       Date:  2014-01-28       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.